Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06228482 · ClinicalTrials.gov registry record · Phase 1
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
A Phase 1 study of Metastatic Nonsmall Cell Lung Cancer, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06228482 is a Phase 1 study of Metastatic Nonsmall Cell Lung Cancer that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06228482, a Phase 1 study of Metastatic Nonsmall Cell Lung Cancer, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Study Locations (1)
California
- The University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06228482
The ClinicalTrials.gov registry entry for NCT06228482 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Nonsmall Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. is the first listed.
NCT06228482 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06228482 about?
NCT06228482 is a clinical study titled "Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6". This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
What is the current status of trial NCT06228482?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-01-22. Estimated completion is 2027-01.
What conditions does trial NCT06228482 study?
This clinical trial studies the following conditions: Metastatic Nonsmall Cell Lung Cancer.
What interventions are being tested in trial NCT06228482?
The interventions under investigation include: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. (DRUG).
Who is sponsoring clinical trial NCT06228482?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06228482 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.